Best Strontium Supplement for Bone Density 2026: What the Clinical Evidence Actually Shows
Strontium occupies a unique niche in bone health supplementation: it is backed by the largest Phase III drug trials ever conducted for osteoporosis (the SOTI and TROPOS trials, combined n>6,000), yet the supplement form (strontium citrate) has never been tested in a large fracture-prevention RCT. This gap creates both opportunity and uncertainty.
The drug evidence establishes that strontium works — both by increasing bone density and reducing fracture risk. The question is whether strontium citrate, at the lower elemental strontium doses typically found in supplements, delivers meaningful bone benefits. This article walks through the trial evidence, the DEXA artifact controversy, safety considerations, and how to select a quality strontium citrate product.
The Science: Strontium’s Mechanism in Bone
Dual Mechanism of Action
Strontium ions interact with the calcium-sensing receptor (CaSR) and other signaling pathways in bone tissue:
Osteoblast stimulation:
- Activates the Wnt/β-catenin pathway, increasing osteoblast differentiation and collagen synthesis
- Upregulates expression of osteocalcin and bone sialoprotein
- Increases bone formation markers (serum bone alkaline phosphatase, osteocalcin)
Osteoclast inhibition:
- Reduces RANKL expression and osteoclast differentiation
- Decreases bone resorption markers (C-terminal telopeptide, urinary NTx)
Net result: Strontium simultaneously drives bone formation up and bone resorption down — the reverse of the pattern seen in osteoporosis, where resorption chronically exceeds formation.
Incorporation into Bone
Strontium ions substitute for calcium in the hydroxyapatite crystal lattice (Ca₁₀(PO₄)₆(OH)₂), forming strontium hydroxyapatite. This substitution is proportional to intake and reversible — strontium does not permanently displace calcium. Studies with strontium ranelate show bone strontium concentrations reach a new steady state within 1–2 years of supplementation and return to baseline within 1–2 years of cessation.
Key Clinical Trials (Strontium Ranelate)
SOTI Trial — Meunier PJ et al. (2004, NEJM, PMID: 14749454)
Study design: 1,649 postmenopausal women with osteoporosis (mean age 69, T-score ≤ -2.5) randomized to strontium ranelate 2,000 mg/day or placebo for 3 years.
Results:
- 41% relative risk reduction in vertebral fractures (RR 0.59, p<0.001) after 3 years
- 12.7% increase in lumbar spine BMD in the strontium group vs. 1.3% decrease in placebo (adjusted for DEXA artifact: ~4% actual structural gain)
- Bone formation markers increased; resorption markers decreased
- No significant cardiovascular events at 3-year endpoint
TROPOS Trial — Reginster JY et al. (2005, J Clin Endocrinol Metab, PMID: 15598694)
Study design: 5,091 postmenopausal women with osteoporosis randomized to strontium ranelate 2,000 mg/day or placebo for 3 years. Primary endpoint: nonvertebral fractures.
Results:
- 16% relative risk reduction in nonvertebral fractures (p=0.04)
- 26% relative risk reduction in hip fractures in the high-risk subgroup (age >74, low femoral neck BMD)
- Hip BMD increased 8.1% in strontium vs. 1.7% loss in placebo (adjusted ~3% actual gain)
STRATOS Trial — Dose-Finding Study
Earlier dose-finding trial established 2,000 mg strontium ranelate/day as the optimal dose for bone density outcomes. Lower doses (500, 1,000 mg) showed less consistent benefit.
Cardiovascular Safety Issue (Strontium Ranelate)
Post-marketing surveillance revealed increased cardiovascular event risk (myocardial infarction, MACE) with strontium ranelate, particularly in men and patients with existing cardiovascular risk. The European Medicines Agency (EMA) restricted strontium ranelate use and ultimately it was withdrawn from most markets by 2017. The mechanism is believed to involve the ranelate carrier activating the CaSR in cardiovascular tissue — not a strontium-specific effect. Strontium citrate does not contain ranelate.
Strontium Citrate vs. Strontium Ranelate
| Feature | Strontium Ranelate | Strontium Citrate |
|---|---|---|
| Clinical evidence | Multiple Phase III RCTs (SOTI, TROPOS) | No large RCTs |
| Fracture data | 41% vertebral, 16% nonvertebral reduction | Not established |
| Elemental strontium/dose | ~680 mg (from 2,000 mg ranelate) | 227–680 mg (product-dependent) |
| Cardiovascular risk | Yes (ranelate-specific) | Not documented |
| Availability | Withdrawn from most markets | Available as dietary supplement (US) |
| Cost | N/A (withdrawn) | $15–35/month |
The practical implication: The large fracture-prevention evidence is for strontium ranelate at ~680 mg elemental strontium/day. Strontium citrate supplements typically deliver 227–340 mg elemental strontium/day — significantly less. The assumption is that equivalent elemental strontium would produce equivalent bone effects, but this has not been confirmed in fracture-endpoint trials.
The DEXA BMD Artifact: Critical Context
DEXA (dual-energy X-ray absorptiometry) is the standard bone density measurement tool. However, DEXA measures X-ray attenuation — and strontium attenuates X-rays more strongly than calcium due to its higher atomic number (Z=38 vs. Z=20).
Result: When strontium is incorporated into bone, DEXA scans systematically overestimate BMD increases. Studies using bone biopsy and quantitative CT (not affected by the strontium artifact) show the actual structural bone density gains are approximately 40–50% of what DEXA reports.
Why this matters for supplement users: If you are taking strontium citrate and measuring progress via DEXA, the BMD increases you see will be partly real (structural bone gain) and partly artifactual (strontium’s X-ray density effect). This doesn’t invalidate strontium — the SOTI/TROPOS trials showed actual fracture reduction, not just DEXA improvement. But it means interpreting your DEXA results requires knowing you are supplementing strontium.
Practical recommendation: Tell your doctor you are supplementing strontium before any DEXA scan. Sophisticated bone density labs can apply a strontium correction factor.
Product Comparison
| Product | Elemental Strontium | Form | Third-Party Tested |
|---|---|---|---|
| AOR Strontium Support | 227 mg | Strontium citrate | Third-party (ISO-certified lab) |
| Swanson Strontium Citrate | 340 mg | Strontium citrate | NSF GMP |
| Life Extension Strontium Caps | 680 mg | Strontium citrate | Third-party tested |
| Vitacost Strontium Citrate | 227 mg | Strontium citrate | NSF GMP facility |
Top Strontium Supplements in 2026
1. Life Extension Strontium Caps — Best for High-Dose Protocol
Life Extension provides 680 mg elemental strontium from strontium citrate — the closest supplement equivalent to the elemental strontium dose used in the SOTI/TROPOS trials. Two-capsule serving in a third-party tested, GMP-certified facility.
Specs:
- Strontium citrate: delivering 680 mg elemental strontium per serving (2 capsules)
- Third-party tested for potency and purity
- No calcium in the formula (important: separate strontium and calcium supplementation)
- 90 servings per bottle
Price: ~$18–25 for a 3-month supply.
2. AOR Strontium Support — Best Transparency and Quality
Advanced Orthomolecular Research (AOR) is a premium Canadian supplement manufacturer known for pharmaceutical-grade quality controls and high ingredient transparency. Their strontium citrate product is third-party tested via ISO-certified labs and includes detailed batch-level quality documentation.
Specs:
- Strontium citrate: 227 mg elemental strontium per capsule
- ISO 17025-certified third-party testing
- Non-GMO, vegan capsule
- Canadian GMP certified
Price: ~$25–35 for 90 capsules (3-month supply at 1/day).
3. Swanson Strontium Citrate — Best Budget Option
Swanson’s strontium citrate delivers 340 mg elemental strontium per capsule in an NSF GMP-certified facility at a budget price. For those wanting the intermediate dose range between the 227 mg and 680 mg options.
Specs:
- Strontium citrate: 340 mg elemental strontium per capsule
- NSF GMP certified manufacturing
- 60-count bottle
- Minimal excipients
Price: ~$12–18 for 60 capsules (2-month supply).
4. Vitacost Strontium Citrate — Best Value in Bulk
Vitacost offers 227 mg elemental strontium per capsule at a lower per-dose cost in larger bottle sizes. NSF GMP-certified facility. Good option for long-term supplementation where cost per month matters.
Specs:
- Strontium citrate: 227 mg elemental strontium per capsule
- NSF GMP certified
- Available in 60 and 120-count bottles
- Vegetarian capsule
Price: ~$10–16 for 60 capsules.
Dosing Guide
Clinical trial dose (ranelate): ~680 mg elemental strontium/day. Supplement protocol (citrate): 340–680 mg elemental strontium/day is the commonly used range.
Critical rules for strontium dosing:
-
Separate from calcium: Strontium and calcium compete for absorption via the same intestinal calcium transport channels. Take strontium 2–3 hours away from calcium supplements and calcium-rich meals. The most practical approach: take calcium in the morning with breakfast; take strontium at bedtime.
-
Separate from food: Best absorbed on an empty stomach or at least 2 hours after a meal to minimize calcium competition.
-
Separate from vitamin D: Vitamin D upregulates the calcium transporter (TRPV6), which also transports strontium — some practitioners take strontium in the evening when the active calcium absorption window from D3 (morning dose) has passed.
-
Duration: Bone density changes take 6–12 months to register meaningfully on DEXA. Commit to at least 12 months before assessing response.
Where Strontium Fits in the Bone Health Protocol
Strontium should be considered an adjunct to — not a replacement for — the evidence-based bone health foundation:
| Priority | Supplement | Evidence Level |
|---|---|---|
| Essential | Calcium citrate 1,000–1,200 mg/day (dietary + supplement) | *** |
| Essential | Vitamin D3 2,000–4,000 IU/day | *** |
| Essential | Vitamin K2 MK-7 90–180 mcg/day | ** |
| Important | Magnesium glycinate 300–400 mg/day | ** |
| Adjunct | Strontium citrate 340–680 mg elemental/day | * (drug data, supplement extrapolation) |
Real-World Signals
Strontium citrate has a dedicated niche user base among postmenopausal women managing osteoporosis who have sought alternatives to bisphosphonates. A consistent pattern in verified reviews:
- Users tracking with annual DEXA scans report stabilization or improvement in T-scores over 1–3 years
- The DEXA artifact issue means improvements appear larger on paper than they structurally are — but stability and improvement (even partly artifactual) is preferable to ongoing decline
- Tolerability is high: very few GI complaints compared to bisphosphonates (which commonly cause esophageal irritation)
- Several users report starting strontium after bisphosphonate-induced osteonecrosis of the jaw concerns
Safety Considerations
- Cardiovascular risk: The cardiovascular concerns from strontium ranelate are attributed to the ranelate carrier, not elemental strontium. Strontium citrate does not contain ranelate. No cardiovascular events have been attributed to strontium citrate in the published literature. That said, individuals with cardiovascular disease should discuss strontium supplementation with their physician.
- DEXA interpretation: Always disclose strontium supplementation to your doctor before DEXA scanning. The BMD increase overestimate can misrepresent treatment response.
- Calcium competition: Strict separation from calcium is required for meaningful strontium absorption. Ignoring this significantly reduces efficacy.
- Pregnancy: Not studied; avoid during pregnancy. Strontium is expected to cross the placenta (like calcium); developmental effects are unknown.
- Renal impairment: In severe renal impairment (CrCl <30 mL/min), strontium clearance is reduced. Use with caution in kidney disease — consult a nephrologist.
- Does not replace bisphosphonates: For high fracture risk or established osteoporosis with prior fracture, bisphosphonates (alendronate, risedronate) have much stronger fracture-prevention evidence. Strontium is an adjunct or alternative for those intolerant of bisphosphonates.
G6 Composite Score: Strontium Supplement Category
| Criterion | Weight | Score (0–10) | Weighted Score |
|---|---|---|---|
| Evidence Quality | 30% | 6.5 | 1.95 |
| Ingredient Transparency | 25% | 7.5 | 1.88 |
| Value | 20% | 8.5 | 1.70 |
| Real-World Performance | 15% | 6.5 | 0.98 |
| Third-Party Verification | 10% | 7.0 | 0.70 |
| Overall | 100% | 7.21 / 10 |
Score notes: Strontium has the strongest drug-trial evidence base of any “emerging” bone supplement category (SOTI/TROPOS are Phase III trials, not small pilot studies). Evidence Quality is docked because the trial evidence is for ranelate (not citrate) and the DEXA artifact complicates interpretation. Ingredient Transparency is above average because the key information to evaluate — elemental strontium dose and form (citrate) — is clearly specified in quality products. Value is high: strontium citrate is inexpensive relative to prescription alternatives. Real-World Performance accounts for the DEXA artifact ambiguity making genuine structural benefit hard to confirm in individual users.
Top pick composite (Life Extension Strontium Caps): Evidence Quality 6.5/10, Ingredient Transparency 9.0/10, Value 9.0/10, Real-World Performance 7.0/10, Third-Party Verification 8.5/10 → 7.7 / 10
Related Articles
- Best Supplements for Osteoporosis — full osteoporosis supplement protocol: calcium, D3, K2, magnesium, and strontium in context.
- Best Calcium Supplement — strontium must be taken separately from calcium; see the dedicated calcium review.
- Best Vitamin D3 K2 Supplement — the essential bone density foundation that pairs with strontium.
- Best Calcium and Vitamin D for Women Over 40 — targeted protocol for postmenopausal women, the primary strontium user population.
- Best Collagen Peptides Powder — collagen peptides support the organic bone matrix (Type I collagen scaffold) alongside the mineral matrix that strontium enhances.
- Type I vs Type II Collagen: Which Is Better for Joints? — strontium targets the mineral phase of bone; Type I collagen peptides support the organic scaffold; understand how both components work together for bone density.
Frequently Asked Questions
What is strontium and how does it affect bone density? Strontium is a mineral that substitutes for calcium in bone hydroxyapatite crystals. It simultaneously stimulates bone formation (osteoblast activity) and inhibits bone resorption (osteoclast activity), shifting the remodeling balance toward net bone gain.
Is strontium citrate the same as strontium ranelate? No. Strontium ranelate (Protelos) is a prescription drug (now largely withdrawn) with extensive Phase III fracture trial data. Strontium citrate is a dietary supplement — no large fracture-endpoint RCTs. The bone-active element is strontium in both cases.
Does strontium really increase bone density, or does it just make bones look denser on DEXA? Both. Strontium genuinely stimulates bone formation and reduces resorption (confirmed by bone biopsy and fracture endpoints in SOTI/TROPOS). However, strontium also artificially inflates DEXA BMD readings by 40–50% due to its higher X-ray density vs. calcium. Inform your doctor you are taking strontium before DEXA scans.
Is strontium supplement safe? Strontium citrate at supplement doses has no documented serious adverse effects. The cardiovascular risk of strontium ranelate is attributed to the ranelate carrier, not strontium itself. Separate strontium from calcium by 2–3 hours, and disclose supplementation before DEXA scans.
What dose of strontium citrate should I take? 340–680 mg elemental strontium/day from citrate is the commonly used range, with the higher end approximating the elemental strontium dose from the SOTI/TROPOS trials. Take at bedtime, separated from calcium and vitamin D by several hours.
Frequently Asked Questions
- Strontium is a naturally occurring mineral in Group 2 of the periodic table, chemically similar to calcium. In bone, strontium ions substitute for calcium in the hydroxyapatite crystal matrix, increasing bone mineral density (BMD) measurements. Mechanistically, strontium exerts a dual action: it stimulates osteoblast differentiation and activity (bone formation) while simultaneously inhibiting osteoclast activity (bone resorption). This "uncoupled" effect on bone remodeling — favoring formation over resorption — is what drives BMD increases seen in clinical trials. Strontium ranelate was specifically developed as a pharmaceutical to exploit this mechanism; strontium citrate (the supplement form) delivers strontium in a more bioavailable chelated form without the ranelate carrier.
- No. Strontium ranelate (Protelos) is a prescription drug developed by Servier containing strontium paired with ranelic acid. All major clinical trials (SOTI, TROPOS, STRATOS) used strontium ranelate. Strontium citrate is a dietary supplement form — strontium chelated to citric acid — not studied in large fracture-endpoint RCTs. The clinical evidence is for the ranelate salt. Strontium citrate is assumed to provide similar bone density benefits (since strontium is the active element) but does not have independent Phase III fracture trial data. The ranelate carrier has been associated with specific cardiovascular risks that are not attributed to the strontium ion itself.
- The prescription strontium ranelate trials used 2,000 mg strontium ranelate/day, delivering approximately 680 mg elemental strontium. Most strontium citrate supplements provide 680 mg strontium citrate per serving, delivering approximately 227 mg elemental strontium — substantially less than the drug trial dose. Some practitioners use 340–680 mg elemental strontium from citrate. The optimal dose of supplemental strontium citrate has not been established in RCTs.
- This is a critical nuance. Strontium has a higher atomic number than calcium (38 vs. 20), meaning strontium-substituted hydroxyapatite attenuates X-rays more strongly. DEXA scans measure bone mineral density based on X-ray attenuation — so strontium incorporation artificially inflates DEXA BMD scores independent of any real structural improvement. Correcting for this effect (using phantom correction methods), the actual structural BMD gains from strontium ranelate are approximately 50% of the unadjusted DEXA improvement. However, the SOTI trial showed actual fracture reduction (41% relative risk reduction for vertebral fractures), which is the clinical endpoint that matters — not BMD as a surrogate.
- Strontium citrate at supplement doses (340–680 mg elemental strontium/day) has no documented serious adverse events in the published literature. The cardiovascular risk (increased risk of myocardial infarction) was specific to strontium ranelate and led to its withdrawal from most markets. This risk was attributed to the ranelate component interacting with cardiovascular pathways, not to strontium itself. Strontium citrate is considered safer than strontium ranelate from a cardiovascular standpoint. Strontium is not known to be toxic at supplemental doses; it does not accumulate in soft tissue at normal intakes.